New TB drug candidate passes first safety check in humans
NCT ID NCT05824091
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called MK-7762 in 119 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo in single or multiple doses. The goal was to check for side effects and measure drug levels in the blood, not to treat tuberculosis. This is a very early step in developing a possible new TB medicine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-7762 (TBD09)
What this could lead to
If successful, this could lead to a new drug for tuberculosis, potentially offering a safer or more effective treatment option.
What could go wrong
This is a very early, first-in-human study focused only on safety in healthy volunteers. It does not test whether the drug actually treats TB, and many early-stage drugs fail to show benefit in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site
Lincoln, Nebraska, 68502, United States